Table 2. aPWV readings in selected subgroups.
Yes | No | P value | |
Male | 10.3±2.0 | 9.7±2.0 | <0.001 |
Diabetes | 10.3±2.0 | 9.8±2.0 | <0.001 |
Previous CVE | 10.3±0.7 | 9.8±0.6 | <0.001 |
Albuminuria* | 10.3±2.0 | 9.8±2.0 | <0.001 |
Hypertension‡ | 10.0±2.0 | 9.1±2.0 | <0.001 |
BP<130/80 at baseline visit | 9.2±1.7 | 10.3±2.1 | <0.001 |
Obese | 9.5±1.9 | 10.1±2.0 | <0.001 |
Age <75 years | 9.1(8.1–10.3) | 10.5(9.4–11.8) | <0.001 |
Anaemia | 10.2±1.9 | 9.8±2 | 0.003 |
Central Obesity | 9.9±2 | 9.5±1.9 | 0.003 |
On antihypertensive medication | 10.0±2.0 | 9.6±2.1 | 0.007 |
CKD stage 3B | 10.1±2 | 9.8±2.1 | 0.009 |
Previous Smoker | 10.0±2.1 | 9.8±1.9 | 0.011 |
Data are presented as mean ± standard deviation or median (interquartile range).
aPWV (aortic pulse wave velocity) readings expressed as m/sec.
Microalbuminuria or greater levels of proteinuria.
CKD 3B = eGFR 30–44 mls/min/1.73 m2; CVE = cardiovascular event;
MAP = Mean arterial pressure;
= Hypertension at entry into study;
Mann U Whitney tests used where data were not normally distributed.